Latest Breaking News On - Live bacterial product - Page 1 : comparemela.com

Evogene : Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF.

Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug

The final patient completes Phase I trial enrollment, evaluating safety and tolerability for Biomica s microbiome-based immuno-oncology drug, BMC128 REHOVOT, Israel, Jan. 17, 2024 /PRNewswire/ .

Evogene Ltd. (NASDAQ:EVGN) Q3 2023 Earnings Call Transcript

Evogene Ltd. (NASDAQ:EVGN) Q3 2023 Earnings Call Transcript November 15, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome to Evogene’s Third Quarter 2023 Results Conference Call. All participants are present in listen-only mode. Following management’s formal presentation, instructions will be given for the question-and-answer session. [Operator Instructions] As a reminder, this conference […]

Biomica Announces First Patient Dosed in its Phase I Study of its Microbiome-Based Immuno-Oncology Drug

Biomica Announces Successful Enrollment of First Patient in its Phase I Study of Microbiome-Based Immuno-Oncology Drug